Projects
Genetic-manipulation-free photothermal stimulation and enhanced photothermal ablation of cardiomyocytes; new and safer tool to cure cardiac arrhythmias. University of Antwerp
New and safer tools to cure cardiac arrhythmias through genetic-manipulation-free photothermal stimulation and enhanced photothermal ablation of cardiomyocytes. University of Antwerp
Elucidating the pathogenicity of genetic variants of uncertain significance in Brugada syndrome patients by functional modelling in hiPSC-derived cardiomyocytes and zebrafish. University of Antwerp
Quantitative approach to assess function and apoptosis changes in the H9C2 cardiomyocyte cell line following differentiation and Doxorubicin exposure KU Leuven
Introduction: For some decades, the anthracycline doxorubicin (DOX) has been used in the treatment of solid tumors and leukemia. It is one of the most widely and successfully applied chemotherapeutic drugs and over the last 20 years has increased the 5-year survival rates for pediatric cancer patients from 58% to 80%. However, the clinical utility and dosage regimens of DOX are often limited by severe side effects.
The most severe side ...
Development and validation of human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) assays to predict functional and structural cardiac liabilities. University of Antwerp
Subcellular Ca2+ signalling microdomains regulating cardiomyocyte growth and function KU Leuven
Analysing and Modulating Apoptosis Sensitisation and Resistance in Cultured and Patient-Derived Cardiac Cells by Quantitative Biochemistry and Computational Systems Biology Implications to Cardiotoxicity and Differentiation. KU Leuven
DNA methylation in cardiac aging and disease and its potential interaction with Ca2+ handling pathways. KU Leuven
Cardiovascular diseases, including heart failure and atrial fibrillation are the leading cause of mortality worldwide. With age the greatest risk factor, their prevalence will substantially increase in the next decades. Factors contributing to this age-associated susceptibility to development of pathology are not established making the identification of new mechanistic targets and prognostic indicators of cardiac health urgently required. ...
Titin Antisense-1, a novel therapeutic target and biomarker in heart failure with preserved ejection fraction. KU Leuven
Heart failure with preserved ejection fraction (HFpEF) is an invalidating and deadly disease, mainly affecting women (2:1). Diabetes, hypertension along with obesity and chronic kidney failure are the main treatable co-morbidities. Still, early diagnostic markers or mortality-reducing drugs are completely lacking. Recently we discovered a novel long non-coding RNA, titin antisense-1 (TTN-AS1), as a promising therapeutic target, and female ...